DRIP1 Polyclonal Antibody, APC-Cy5.5 Conjugated
Applications
Reactivity
| Overview | |
| Catalog # | bs-9618R-APC-Cy5.5 |
| Product Name | DRIP1 Polyclonal Antibody, APC-Cy5.5 Conjugated |
| Applications |
WB
IF(IHC-P)
|
| Reactivity | Human, Mouse, Rat |
| Specifications | |
| Conjugation | APC-Cy5.5 |
| Host | Rabbit |
| Source | KLH conjugated synthetic peptide derived from human DRIP1/C14orf28 |
| Clonality | Polyclonal |
| Isotype | IgG |
| Concentration | 1ug/ul |
| Purification | Purified by Protein A. |
| Storage Buffer | Aqueous buffered solution containing 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Storage Condition | Store at -20C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target | |
| Gene ID | 122525 |
| Synonyms | CN028_HUMAN; Dopamine receptor interacting protein 1; Dopamine receptor-interacting protein 1; DRIP 1; DRIP1; Uncharacterized protein C14orf28; C14orf28. |
| Background | 1.C14ORF28, GNB2L1, MLLT3, DRD2 and DARPP-32 are important in the pathogenesis of schizophrenia and bipolar disorder; 2. these two disorders share common disease-related mechanisms linked to dopamine signalling; 3. the expression of these genes is closely correlated; and 4. DRD2 provides the initial trigger in the pathogenesis of these disorders. |
| Application Dilution | |
| WB | 1:300-5000 |
| IF(IHC-P) | 1:50-200 |